adjuvant

News

Merck fights back against Roche in adjuvant lung cancer ther...

Merck & Co's Keytruda is poised to move even earlier in the treatment of patients with non-small cell lung cancer (NSCLC) after showing efficacy when used to prevent the cancer returnin

News

GSK gets £1.4bn sales lift from COVID-19 products in 2021

GlaxoSmithKline's COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive E

News

Merck gets EU nod for Keytruda in adjuvant kidney cancer

Merck & Co has passed another milestone in its drive to move PD-1 inhibitor Keytruda earlier in the treatment pathway for cancer, with the European Commission approving use of the drug

News

Chasing Roche, Merck unveils adjuvant lung cancer data for K...

Merck & Co's Keytruda is the undisputed market leader in immunotherapy for non-small cell lung cancer (NSCLC), but was leapfrogged by Roche's Tecentriq in the early-stage, adjuvant trea

News

NICE gives Keytruda parity with Opdivo for adjuvant melanoma

After three years of availability via the Cancer Drugs Fund (CDF), MSD's checkpoint inhibitor Keytruda has now been approved for routine NHS use after surgery for people with melanoma to pr

News

Merck claims another adjuvant okay from FDA for Keytruda

Merck & Co's strategy of pushing Keytruda earlier in the treatment pathway for cancers has secured anther victory, after the FDA approved the immunotherapy for adjuvant treatment of ski

Merck fights back against Roche in adjuvant lung cancer ther...

GSK gets £1.4bn sales lift from COVID-19 products in 2021

Merck gets EU nod for Keytruda in adjuvant kidney cancer

Chasing Roche, Merck unveils adjuvant lung cancer data for K...

NICE gives Keytruda parity with Opdivo for adjuvant melanoma

Merck claims another adjuvant okay from FDA for Keytruda

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

adjuvant

Editor's Picks